Nuclear expression of aryl hydrocarbon receptor and prognosis for non-small lung cancer. Background: Wee1 regulates G2 checkpoint signaling by phosphorylating and inactivating cyclin-dependent kinase1 ...
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven ...
PARP inhibitors such as Merck and AstraZeneca’s Lynparza have changed the game for patients with ovarian cancer, but they’re still not a cure, as cancers can outsmart these drugs and develop ...
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 Uterine serous carcinoma (USC) is a distinct ...
Zentalis Pharma has shelved its oral SERD and EGFR inhibitors due to competition and focused on ZN-c3, an inhibitor of WEE1. AZN left the WEE1 space last year, which is a cause for both worry and ...
DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE)-- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery ...
DOYLESTOWN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (APRE) (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new ...
About MUIR Clinical Trial MUIR (ZN-c3-002) is a multi-part, open-label Phase 1b clinical trial (NCT04516447) evaluating the safety, efficacy, and preliminary clinical activity of azenosertib in ...
Compelling Preclinical Activity in Triple-Negative Breast Cancer with Azenosertib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results